Yves Fouron
Directeur/Membre du Conseil chez Bellus Health (Innodia), Inc.
Profil
In addition to his current role with Transfer Technologies, Dr. Fouron is a Director of PainCeptor Pharma Corp.
and Innodia, Inc. Previously, he was President and Chief Executive Officer of Immuno-Designed Molecules, Vice President of Technical Services for Coley Pharmaceutical Group and Vice-President of Business Development for Sepracor, Inc. Dr. Fouron co-founded Chembiomed Ltd.
and served as Vice President of Business Development.
He has several years of senior technical and business management experience in biotechnology companies.
Postes actifs de Yves Fouron
| Sociétés | Poste | Début |
|---|---|---|
Bellus Health (Innodia), Inc.
 Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | Directeur/Membre du Conseil | - |
Anciens postes connus de Yves Fouron
| Sociétés | Poste | Fin |
|---|---|---|
Chronogen, Inc.
 Chronogen, Inc. Pharmaceuticals: MajorHealth Technology Chronogen, Inc. develops drugs to treat age-dependent diseases. It manufactures drugs for neurodegenerative, cardiovascular, ischemia and reperfusion injury, and dyslipidemia diseases. The company was founded by Siegfried Hekimi in April 1998 and is headquartered in Montréal, Canada | Président | 23/04/2010 |
CDP Capital Private Equity
 CDP Capital Private Equity Investment ManagersFinance CDP Capital Private Equity (CDPQ) is a private equity subsidiary of The Caisse de dépôt et placement du Québec founded in 1995. The firm is headquartered in Montréal with additional office in London. | Directeur en chef des Investissements | 31/03/2007 |
Transfer Technologies Commercialisation Capital
 Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Corporate Officer/Principal | - |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Corporate Officer/Principal | - |
| Immuno-Designed Molecules SA | President | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
| Immuno-Designed Molecules SA | Health Technology |
CDP Capital Private Equity
CDP Capital Private Equity Investment ManagersFinance CDP Capital Private Equity (CDPQ) is a private equity subsidiary of The Caisse de dépôt et placement du Québec founded in 1995. The firm is headquartered in Montréal with additional office in London. | Finance |
PainCeptor Pharma Corp.
 PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Health Technology |
Targanta Therapeutics, Inc.
 Targanta Therapeutics, Inc. BiotechnologyHealth Technology Targanta Therapeutics, Inc. develops antibiotic drugs and other related products. It focuses on developing and commercializing novel antibacterial agents to address unmet medical needs in the hospital market. The company also develops antibacterial pro-drugs for the treatment and prevention of bone infections. Targanta Therapeutics was founded in May 2007 and is located in St. Laurent, Canada | Health Technology |
Chronogen, Inc.
Chronogen, Inc. Pharmaceuticals: MajorHealth Technology Chronogen, Inc. develops drugs to treat age-dependent diseases. It manufactures drugs for neurodegenerative, cardiovascular, ischemia and reperfusion injury, and dyslipidemia diseases. The company was founded by Siegfried Hekimi in April 1998 and is headquartered in Montréal, Canada | Health Technology |
Bellus Health (Innodia), Inc.
Bellus Health (Innodia), Inc. Pharmaceuticals: MajorHealth Technology Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada. | Health Technology |
Transfer Technologies Commercialisation Capital
Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Finance |